Serum decoy receptor 3, a potential new biomarker for sepsis

Hou, Yanping; Xu, Ping; Zhang, Mei; Han, Deping; Peng, Liang; Dong, Liang; Yang, Shanmin; Zhang, Zhenhuan; Hong, Jinsheng; Lou, Xiaoli; Zhang, Lurong; Kim, Sunghee

doi:10.1016/j.cca.2012.01.007

Cited by 26 publications

(28 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hou et al, (2012) [21] also agreed with our results as they found that the serum DcR3 was significantly increased in sepsis patients compared with SIRS patients and healthy controls (6.11±2.58 ng/ml vs 2.62±1.46 ng/ml, and 0.91±0.56 ng/ml, respectively, p<0.001). In addition, the DcR3 exhibited a positive correlation with the APACHE II("Acute Physiology and Chronic Health Evaluation II") score, a most commonly used index for the severity of sepsis.…”

Section: World Journal Of Pharmacy and Pharmaceutical Sciencessupporting

confidence: 92%

Rapid and Specific Diagnosis of Bacterial Sepsis in High Risk Patients

Ali¹

2017

WJPPS

View full text Add to dashboard Cite

Sepsis is a major healthcare problem worldwide, athe accurate and timely detection of sepsis remains a challenge specially in high risk This study was performed on 80 subjects (52 subjects suggestive to be bacterial sepsis patients and 28 subjects apparently healthy blood donors as a control).Peripheral venous blood was collected to be utilized for polymerase chain reaction and serum used for measurement of DCR3 by (EIA). Twenty five samples were PCR positive(48%) and 27 samples were PCR negative PCR with sensitivity, specificity, positive predictive value and negative predictive value 100,90, 88 and 100 respectively. The average DCR3 level was 10.35 fold than the control group in sepsis and We recommended that the amplification of 16s ribosomal DNA by PCR providing highly sensitive and time saving diagnostic technique and measurement of DCR3 by EIA provide a noninvasive, specific biomarker for prediction of bacterial sepsis progression and discrimination between bacterial sepsis and systemic inflammatory response syndrome.

show abstract

Section: World Journal Of Pharmacy and Pharmaceutical Sciencessupporting

confidence: 92%

Rapid and Specific Diagnosis of Bacterial Sepsis in High Risk Patients

Ali¹

2017

WJPPS

View full text Add to dashboard Cite

show abstract

“…Reagents for DcR3 ELISA were kindly provided by Dr. Lurong Zhang as previously described (Hou et al 2012). Briefly, high-affinity polystyrene 96-well microtiter plates (Costar 2592, Corning) were coated with anti-DcR3 monoclonal antibody (2.0 μg/ml, 100 μl/well) overnight at 4°C.…”

Section: Dcr3 Enzyme-linked Immunosorbent Assay (Elisa)mentioning

confidence: 99%

Serum Decoy Receptor 3 Is a Useful Predictor for the Active Status of Chronic Hepatitis B in Hepatitis B e Antigen-Negative Patients

Hou

Lou

et al. 2013

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a global public health problem, because patients with chronic hepatitis B (CHB) may progress to liver cirrhosis and eventually evolve into hepatocellular carcinoma. Decoy receptor 3 (DcR3) is a soluble receptor of the tumor necrosis factor receptor superfamily, and has been implicated in anti-apoptotic and anti-inflammatory pathways. In this study, we explored the clinical value of serum DcR3 in predicting the active status of CHB in hepatitis B e antigen-negative patients (active HBeAg (−) CHB), which was determined with ELISA. The serum level of DcR3 in active HBeAg (−) CHB patients (1.92 ± 0.68 ng/ml) was higher than that in healthy controls (0.80 ± 0.25 ng/ml, p < 0.0001) and that in inactive status of HBeAg (−) CHB (inactive hepatitis B surface antigen carrier, HBsAg-IaC) patients (0.95 ± 0.26 ng/ml, p < 0.0001). DcR3 level was correlated with HBV DNA level (r = 0.819, p < 0.0001) and alanine transaminase level (ALT, r = 0.704, p < 0.0001) in active HBeAg (−) CHB patients. The area under the Receiver Operating Characteristics curve of DcR3 for detecting the active status of HBeAg (−) CHB patients was 0.914 (95% confidence interval, 0.851-0.977). The optimal cut-off value for DcR3 to predict active HBeAg (−) CHB was 1.22 ng/ml, which had a sensitivity of 87.5% and a specificity of 84.4%. These results suggest that serum DcR3 level may be useful for detecting HBeAg (−) CHB in the active stage, which requires medical treatment.

show abstract

“…Decoy receptor 3 (DcR3) belongs to the tumor necrosis factor (TNF) receptor family along with DcR1 and -2 and osteoprotegerin (23,24). It binds three TNF family cytokines (FasL, LIGHT [homologous to lymphotoxin, exhibits inducible expression and competes with herpes simplex virus glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes], and TL1A [TNF-like cytokine 1A]) and can protect cancer cells in vitro from Fas/FasL-mediated apoptosis.…”

Section: Dcr3mentioning

confidence: 99%

“…Two studies examined the use of serum DcR3 to distinguish between sepsis and SIRS (23,24). The first study included 118 healthy, age-matched controls, 24 patients with a diagnosis of sepsis (variable infectious sources), and 43 patients classified as having SIRS (negative for any pathogen on culture).…”

Section: Dcr3mentioning

confidence: 99%

“…The soluble urokinase-type plasminogen activator receptor (suPAR) is a component of the urokinase-type plasminogen activator system whose main function includes cell migration and adhesion, tissue remodeling, and pericellular proteolytic processes (9,23). Under conditions of inflammation and infection, including bacteremia, malaria, and certain viral infections, including HIV, suPAR serum levels (predominantly expressed by WBCs) are elevated.…”

Section: Suparmentioning

confidence: 99%

See 1 more Smart Citation

Laboratory Diagnosis of Sepsis? No SIRS, Not Just Yet

Dunne

2015

J Clin Microbiol

View full text Add to dashboard Cite

In order to maximize the benefit of prompt antimicrobial therapy and avoid the risk associated with inappropriate use of antimicrobial agents, patients with suspected sepsis must be rapidly differentiated from patients with systemic inflammatory response syndrome (SIRS). In combination with standard microbiological testing, a number of biomarkers have been recently evaluated for this purpose, and the performance characteristics of the most promising of these are reviewed.T he title of this minireview is somewhat misleading, because sepsis is not a laboratory diagnosis and cannot be defined (at least not yet) using any number of discrete diagnostic assays in the absence of clinical criteria. A positive blood culture, for example, regardless of the organism's identity, is useful supplemental information but does not by itself indicate a septic state. In fact, the recovery of a potential pathogen from any site (1), including blood (2), occurs in less than 50% of all cases of sepsis, and contamination of blood cultures can cloud the interpretation. From the opposite direction, it is difficult to distinguish sepsis from systemic inflammatory response syndrome (SIRS) using clinical criteria alone (3).A few definitions might help clarify the ambiguity here (4, 5). Some of these definitions have been refined over the years, but the general gist remains the same. "SIRS" was first defined in 1991 (4) and refers to "the systemic inflammatory response to a variety of severe clinical insults" (infectious or otherwise). It usually constitutes two or more of the following criteria: (i) temperature of Ͼ38°C or Ͻ36°C; (ii) heart rate of Ͼ90 beats/min; (iii) respiratory rate of Ͼ20 breaths/min or partial CO 2 pressure (pCO 2 ) of Ͻ32 mm Hg; (iv) white blood cell (WBC) count of Ͼ12,000 (12K)/l or Ͻ4K/l; or (v) Ͼ10% immature forms (i.e., bands). "Sepsis" has been defined as "the presence (probable or documented) of infection together with systemic manifestations of infection" (5). Having positive cultures supporting an infectious process adds credibility to the diagnosis but is not mandatory. Therefore, a patient can be classified as septic with Ն2 SIRS criteria and a clinical suspicion of infection without microbiological documentation. Bear this in mind when reading the remainder of this minireview. Most septic patients have SIRS, but not all SIRS patients are septic (Fig. 1). Severe sepsis adds an element of organ dysfunction or tissue hypoperfusion that is new and not explained by other causes of organ dysfunction (4). Finally, "septic shock" is "sepsis-induced hypotension persisting despite adequate fluid resuscitation" (4). Definitions specific for adult and pediatric populations are available (4-6).Sepsis is a major cause of morbidity and mortality among critically ill patients, and the management of septic shock profits from administration of early and appropriate antimicrobial therapy (7). Given that sepsis is only a subset of SIRS and that administration of antimicrobial therapy is not beneficial and indeed could generate...

show abstract

Serum decoy receptor 3, a potential new biomarker for sepsis

Cited by 26 publications

References 41 publications

Rapid and Specific Diagnosis of Bacterial Sepsis in High Risk Patients

Rapid and Specific Diagnosis of Bacterial Sepsis in High Risk Patients

Serum Decoy Receptor 3 Is a Useful Predictor for the Active Status of Chronic Hepatitis B in Hepatitis B e Antigen-Negative Patients

Laboratory Diagnosis of Sepsis? No SIRS, Not Just Yet

Contact Info

Product

Resources

About